Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hepenofovir Fumarate in Chronic Hepatitis B
NCT06122454Phase 2Unknown
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Hepenofovir in Chronic Hepatitis B (CHB) (4 arms), sponsored by Xi'an Xintong Pharmaceutical Research Co., Ltd. Primary endpoints: Quantification of HBV DNA at Week 48, Quantification of HBV markers at Week 48 and 2 more. Status: unknown.
02
Drugs
Hepenofovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06122454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06122454.